BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 16105559)

  • 1. Antimicrobial activity and pharmacokinetics/pharmacodynamics of the novel glycylcycline, tigecycline.
    Peterson LR
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):163-4. PubMed ID: 16105559
    [No Abstract]   [Full Text] [Related]  

  • 2. Antimicrobial activity of tigecycline against clinical isolates from Spanish medical centers. Second multicenter study.
    Betriu C; Rodríguez-Avial I; Gómez M; Culebras E; López F; Alvarez J; Picazo JJ;
    Diagn Microbiol Infect Dis; 2006 Dec; 56(4):437-44. PubMed ID: 16949245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002.
    Bouchillon SK; Hoban DJ; Johnson BM; Stevens TM; Dowzicky MJ; Wu DH; Bradford PA
    Diagn Microbiol Infect Dis; 2005 Apr; 51(4):291-5. PubMed ID: 15808321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Tigecycline, the first of a new class of antibiotics: the glycylcyclines].
    Bosó-Ribelles V; Roma-Sánchez E; Salavert-Lletí M; Hernández-Martí V; Poveda-Andrés JL
    Rev Esp Quimioter; 2007 Mar; 20(1):19-35. PubMed ID: 17530033
    [No Abstract]   [Full Text] [Related]  

  • 5. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms.
    Garrison MW; Neumiller JJ; Setter SM
    Clin Ther; 2005 Jan; 27(1):12-22. PubMed ID: 15763603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapeutic efficacy, animal models and experimental pharmacodynamics: what do we know about tigecycline?].
    Giménez MJ; Barberán J; Aguilar L
    Rev Esp Quimioter; 2007 Dec; 20(4):387-94. PubMed ID: 18563212
    [No Abstract]   [Full Text] [Related]  

  • 7. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004).
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):195-201. PubMed ID: 16105564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).
    Hoban DJ; Bouchillon SK; Johnson BM; Johnson JL; Dowzicky MJ;
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):215-27. PubMed ID: 16105567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tigecycline: a novel glycylcycline antibiotic.
    Zhanel GG; Karlowsky JA; Rubinstein E; Hoban DJ
    Expert Rev Anti Infect Ther; 2006 Feb; 4(1):9-25. PubMed ID: 16441206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents.
    Sader HS; Jones RN; Stilwell MG; Dowzicky MJ; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):181-6. PubMed ID: 16105562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tigecycline in vitro activity against gram-negative and gram-positive pathogens collected in Italy.
    Roveta S; Marchese A; Debbia EA
    Chemotherapy; 2008; 54(1):43-9. PubMed ID: 18073470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).
    Bouchillon SK; Hoban DJ; Johnson BM; Johnson JL; Hsiung A; Dowzicky MJ;
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):173-9. PubMed ID: 16105561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
    Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
    Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tigecycline.
    Pankey GA
    J Antimicrob Chemother; 2005 Sep; 56(3):470-80. PubMed ID: 16040625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Part X. Tetracycline and glycylcycline antimicrobials.
    Vincent S; Bronze MS; Cooper TW; Greenfied RA
    J Okla State Med Assoc; 2007 Jun; 100(6):241-7. PubMed ID: 17708423
    [No Abstract]   [Full Text] [Related]  

  • 17. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
    Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tigecycline: first of a new class of antimicrobial agents.
    Rose WE; Rybak MJ
    Pharmacotherapy; 2006 Aug; 26(8):1099-110. PubMed ID: 16863487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent.
    Meagher AK; Ambrose PG; Grasela TH; Ellis-Grosse EJ
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):165-71. PubMed ID: 16105560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tigecycline: a review of a new glycylcycline antibiotic.
    Scheinfeld N
    J Dermatolog Treat; 2005; 16(4):207-12. PubMed ID: 16249141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.